Jump to content

User:H2OBear/sandbox

From Wikipedia, the free encyclopedia

An extracellular vesicle (EV) is a lipid bilayer-delimited particle that is naturally released from a cell and cannot replicate. EVs range in diameter from near the size of the smallest physically possible unilamellar liposome (around 20-30 nm) to as large as 10 microns or more. They carry a cargo of proteins, nucleic acids, metabolites, and even organelles from the parent cell. Most cells that have been studied to date are thought to release EVs, including some bacterial, fungal, and plant cells that are surrounded by cell walls. A wide variety of EV subtypes have been proposed, defined variously by size, biogenesis pathway, cargo, cellular source, and function.

Numerous functions of EVs have been established or postulated. The first evidence for the existence of EVs was enabled by the ultracentrifuge, the electron microscope, and functional studies of coagulation in the mid-20th century. A sharp increase in interest in EVs occurred in the first decade of the 20th century following the discovery that EVs could transfer nucleic acids from cell to cell. Associated with EVs from certain cells or tissues, nucleic acids could be easily amplified as markers of disease and also potentially traced back to a cell of origin, such as a tumor cell. The discovery also implied that EVs could be used for therapeutic purposes, such as delivering nucleic acids or other cargo to diseased tissue. This growing interest was paralleled by formation of companies and funding programs focused on development of EVs as biomarkers or therapies of disease, the founding of an International Society for Extracellular Vesicles (ISEV), and establishment of a scientific journal devoted to the field, the Journal of Extracellular Vesicles.

Background/History

[edit]

Evidence for the existence of EVs and their functions was first gathered by combined applications of ultracentrifugation, electron microscopy, and functional studies during the mid-20th century. Ultracentrifuged pellets from blood plasma were reported to have procoagulant properties by Erwin Chargaff and Randolph West in 1946.[1] The platelet derivation and lipid-containing nature of these particles was further articulated by Peter Wolf.[2] Around the same time, H. Clarke Anderson and Ermanno Bonucci separately described the calcifying properties of EVs in bone matrix.[3]

Although the extracellular and vesicular properties of EVs had been recognized by numerous groups by the 1970s, the term “extracellular vesicle” was first used in a manuscript title in 1971.[4] This electron microscopy study of the flagellate freshwater alga Ochromonas danica reported release of EVs from membranes including those of flagella. Soon thereafter, EVs were seen to be released from follicular thyroid cells of the bat during arousal from hibernation, suggesting the possible involvement of EVs in endocrine processes.[5] Reports of EVs in intestinal villi samples and, for the first time, in material from human cancer (adenoma)[6] referred back to even earlier publications that furnished similar evidence, although conclusions about EV release had not then been drawn. EVs were also described in bovine serum and cell culture conditioned medium[7] with distinctions made between “vesicles of the multivesicular body” and “microvesicles.”[8] These studies further noted the similarities of EVs and enveloped viruses.

In the early- to mid-1980s, the Stahl and Johnstone labs forged a deeper understanding of the release of EVs from reticulocytes[9][10][11], while progress was also made on EVs shed from tumor cells.[12] The reticulocyte research, in particular, showed that EVs could be released not only from the plasma membrane, but also by fusion of the multivesicular body with the plasma membrane. During this time, EVs were described by many names, sometimes in the same manuscript, such as “shedding vesicles,” “membrane fragments,” “plasma membrane vesicles,” “micro-vesicles/microvesicles,” “exosomes,” (previously used for mobile, transforming DNA elements in model organisms like Drosophila and Neurospora[13][14]), “inclusion vesicles,” and more, or referred to by organ of origin, such as “prostasomes” that were found to enhance sperm motility in semen.[15]

The involvement of EVs in immune responses became increasingly clear in the 1990s with findings of the group of Graça Raposo and others.[16] A clinical trial of dendritic cell-derived EVs was performed in France just before the turn of the century (add detailles).[17] Cells of the immune system were found capable of transferring transmembrane proteins via EVs. For example, the HIV co-receptors CCR5 and CXCR4 could be transferred from an HIV-susceptible cell to a refractory cell by "microparticles," rendering the recipient cell permissive to infection.[18][19]

Beginning in 2006, several laboratories reported that EVs contain nucleic acids and have the ability to transfer them from cell to cell.[20][21][22][23][24][25] Some RNAs were even found to be function in the recipient cell. Whether carrying RNA, surface molecules, or other factors, the involvement of EVs in cancer progression aroused considerable interest,[26] leading to hypotheses that specific EVs could target specific cells due to "codes" displayed on their surface;[27] create or enhance a metastatic niche;[28] betray the presence of specific cancers;[29] or be used as a therapy to target cancer cells.[30] Meanwhile, strides were made in the understanding of vesicle biogenesis and subtypes.[31][32][33][34]

Rapid growth of the EV research community in the early 2000s led to the creation of the International Society for Extracellular Vesicles (ISEV), which has led efforts for rigor and standardization in the field including establishment of the Journal of Extracellular Vesicles. A plethora of national and regional EV societies have also been formed. In 2012, the Director’s Office of the US National Institutes of Health (NIH) announced a program for funding of EV and extracellular RNA studies, the Extracellular RNA Communication Consortium (ERCC),[35] which subsequently invested >USD 100 million in EV research. A second round of funding was announced in 2018. Commercial investment in EV diagnostics and therapeutics also grew during this time. Exosome Diagnostics has developed several cancer diagnostic assays based in part on EV RNA.[36] Codiak Biosciences is a company with intellectual property in the pancreatic cancer space.[37]

Biogenesis and nomenclature

[edit]

Diverse EV subtypes have been proposed, with names such as ectosomes, microvesicles, microparticles, exosomes, oncosomes, apoptotic bodies, and more. These EV subtypes have been defined by various, often overlapping, definitions, based mostly on biogenesis (cell pathway, cell or tissue identity, condition of origin).[38] However, EV subtypes may also be defined by size, constituent molecules, function, or method of separation. Because of the bewildering and sometimes contradictory definitions of different EV subtypes, the current scientific consensus is that “extracellular vesicle” and variations thereon are the preferred nomenclature unless specific biogenetic origin can be demonstrated.[39] Subtypes of EVs may be defined by:

"a) physical characteristics of EVs, such as size (“small EVs” (sEVs) and “medium/large EVs” (m/lEVs), with ranges defined, for instance, respectively, <100nm or <200nm [small], or >200nm [large and/or medium]) or density (low, middle, high, with each range defined); b) biochemical composition (CD63+/CD81+- EVs, Annexin A5-stained EVs, etc.); or c) descriptions of conditions or cell of origin (podocyte EVs, hypoxic EVs, large oncosomes, apoptotic bodies).

[40]

Ectosome/microvesicle/microparticle (plasma membrane origin)

[edit]

The terms “ectosome,” “microvesicle” (MV), and “microparticle” (MP) refer to particles released from the surface of cells. Especially in the field of platelet research, MP has been the standard nomenclature. Formation of ectosomes may in some cases result from directed processes, and in others from shear forces or adherence of the PM to a surface.

Exosome (endosomal origin)

[edit]

Exosome biogenesis begins with pinching off of endosomal invaginations into the multivesicular body (MVB), forming intraluminal vesicles (ILVs). If the MVB fuses with the plasma membrane, the ILVs are released as “exosomes.” It should be noted that the first publication to use the term “exosome” for EVs presented it as a synonym for “micro-vesicle.”Cite error: A <ref> tag is missing the closing </ref> (see the help page).[41] and may reach 20 microns or more in diameter. These large EVs are practically cells except without full nuclei. They contain a functional cytoskeleton and energy sources (mitochondria), and may be motile, contributing to metastasis.[42] Another class of large EV has been observed in neurons of the model organism C. elegans.[43] When injected with a dye, neurons were observed to sequester the dye into a portion of the cell and release it in a large EV dubbed the “exopher.”[44] This body was hypothesized to be a mechanism for disposal of unwanted cellular material. Technically, the platelets of certain vertebrates (which bud from megakaryocytes), as well as red blood cells (e.g., of adult humans) also fulfill the consensus definition of EVs.[45]

Enveloped virus

[edit]

Enveloped viruses are a type of EV produced under the influence of viral infection. That is, the virion is composed of cellular membranes but contains proteins and nucleic acids produced from the viral genome. Some enveloped viruses can infect other cells even without a functional virion, when genomic material is transferred via EVs. Certain non-enveloped viruses may also reproduce with assistance from EVs.[46]

Exomere

[edit]

The “exomere” is a recently discovered particle type that may be related to EVs.[47] in the size range of small EVs (as separated by asymmetric flow field-flow fractionation), the relationship of exomeres to EVs remains to be elucidated.

EV separation and concentration

[edit]

Studying EVs and their cargo typically requires separation from a biological matrix (such as a complex fluid or tissue) so that the uniquely EV components can be analyzed. Many approaches have been used, including differential ultracentrifugation, density gradient ultracentrifugation, size exclusion chromatography, ultrafiltration, and affinity/immunoaffinity capture methods.[48][49][50] Each method has its own recovery and purity outcomes: that is, what percentage of input EVs are obtained, and the ratio of “true” EV components to co-isolates. EV separation can also be influenced by pre-analytical variables.[51][52][53]

EV characterization

[edit]

Population-level EV analysis

[edit]

Separated or concentrated populations of EVs may be characterized by several means. Total concentration of molecules in categories such as protein, lipid or nucleic acid. Total particle counts in a preparation can also be estimated, for example by light-scattering techniques. It should be noted, however, that each measurement technology may have a specific size range for accurate quantitation, and that very small EVs (<100 nm diameter) are not detected by many technologies. Molecular “fingerprints” of populations can be obtained by “omics” technologies like proteomics, lipidomics, and RNomics, or by techniques like Raman spectroscopy. Overall levels of unique molecules can also be measured in the population, such as tetraspanins, phosphatidylserine, or species of RNA. It has been proposed that purity of an EV preparation can be estimated by examining the ratio of one population-level measurement to another, e.g., the ratio of total protein or total lipid to total particles.

Single-particle analysis

[edit]

Specialized methods are needed to study EVs at the single particle level. The challenge for any putative single-particle method is to identify the individual EV as a single, lipid-bilayer particle, and to provide additional information such as size, surface proteins, or nucleic acid content. Methods that have been used successfully for single-EV analysis include optical microscopy and flow cytometry (for large EVs, usually >200 nm), electron microscopy (no lower bound), single-particle interferometric reflectance imaging (down to about 40 nm), and nano-flow cytometry (also to 40 nm). Some technologies allow the study of individual EVs without extensive prior separation from a biological matrix: to give a few examples, electron microscopy and flow cytometry.

Enriched and depleted markers

[edit]

To demonstrate the presence of EVs in a preparation, as well as the relative depletion of non-EV particles or molecules, EV-enriched 'and' -depleted markers are necessary:[54] For example, the MISEV2018 guidelines recommend:

At least one membrane-associated marker as evidence of the lipid bilayer (e.g., a tetraspanin protein)
At least one cytoplasmic but ideally membrane-associated marker to show that the particle is not merely a membrane fragment
At least one “negative” or “depleted” marker: a “deep cellular” marker, a marker of a non-EV particle, or a soluble molecule not thought to be associated with EVs.[55]

Usually, but not necessarily, the EV-enriched or -depleted markers are proteins that can be detected by Western blot, ELISA, mass spectrometry, or other widely-available methods. Assaying for depleted markers is thought to be particularly important, as otherwise the purity of an EV preparation cannot be claimed. However, most studies of EVs prior to 2016 did not support claims of the presence of EVs by showing enriched markers, and <5% measured the presence of possible co-isolates/contaminants.Cite error: A <ref> tag is missing the closing </ref> (see the help page).

Biological functions of EVs

[edit]

A wide variety of biological functions have been ascribed to EVs.

“Trash disposal”: eliminating unwanted materials
Transfer of functional proteins
Transfer of functional RNA
Molecular recycling or “nutrition”
Signaling to the recipient cell via cell-surface or endosomal receptors
Creation of a metastatic niche for cancer
Pathfinding through the environment
Quorum sensing
Mediating host-commensal or parasite/pathogen interaction

EVs as biomarkers and therapeutics

[edit]

References

[edit]
  1. ^ CHARGAFF E; WEST R (1946). "The biological significance of the thromboplastic protein of blood". The Journal of Biological Chemistry. 166 (1): 189–197. doi:10.1016/S0021-9258(17)34997-9. PMID 20273687.
  2. ^ Wolf, P. (1967). "The nature and significance of platelet products in human plasma". British Journal of Haematology. 13 (3): 269–288. doi:10.1111/j.1365-2141.1967.tb08741.x. PMID 6025241. S2CID 19215210.
  3. ^ PMID 5775794, 5412827
  4. ^ Aaronson, S.; Behrens, U.; Orner, R.; Haines, T. H. (1971). "Ultrastructure of intracellular and extracellular vesicles, membranes, and myelin figures produced by Ochromonas danica". Journal of Ultrastructure Research. 35 (5): 418–430. doi:10.1016/s0022-5320(71)80003-5. PMID 4111037.
  5. ^ Nunez, E. A.; Wallis, J.; Gershon, M. D. (1974). "Secretory processes in follicular cells of the bat thyroid. 3. The occurrence of extracellular vesicles and colloid droplets during arousal from hibernation". The American Journal of Anatomy. 141 (2): 179–201. doi:10.1002/aja.1001410203. PMID 4415703.
  6. ^ PMID 53415, 53703, 165305, 4834422
  7. ^ PMID 165305, 4834422
  8. ^ Dalton, A. J. (1975). "Microvesicles and vesicles of multivesicular bodies versus "virus-like" particles". Journal of the National Cancer Institute. 54 (5): 1137–1148. doi:10.1093/jnci/54.5.1137. PMID 165305.
  9. ^ Pan, B. T.; Johnstone, R. M. (1983). "Fate of the transferrin receptor during maturation of sheep reticulocytes in vitro: Selective externalization of the receptor". Cell. 33 (3): 967–978. doi:10.1016/0092-8674(83)90040-5. PMID 6307529. S2CID 33216388.
  10. ^ Harding, C.; Heuser, J.; Stahl, P. (1984). "Endocytosis and intracellular processing of transferrin and colloidal gold-transferrin in rat reticulocytes: Demonstration of a pathway for receptor shedding". European Journal of Cell Biology. 35 (2): 256–263. PMID 6151502.
  11. ^ Johnstone, R. M.; Adam, M.; Hammond, J. R.; Orr, L.; Turbide, C. (1987). "Vesicle formation during reticulocyte maturation. Association of plasma membrane activities with released vesicles (Exosomes)". The Journal of Biological Chemistry. 262 (19): 9412–9420. doi:10.1016/S0021-9258(18)48095-7. PMID 3597417.
  12. ^ Dvorak, H. F.; Quay, S. C.; Orenstein, N. S.; Dvorak, A. M.; Hahn, P.; Bitzer, A. M.; Carvalho, A. C. (1981). "Tumor shedding and coagulation". Science. 212 (4497): 923–924. doi:10.1126/science.7195067. PMID 7195067.
  13. ^ Fox, A. S.; Yoon, S. B. (1970). "DNA-induced transformation in Drosophila: Locus-specificity and the establishment of transformed stocks". Proceedings of the National Academy of Sciences of the United States of America. 67 (3): 1608–1615. doi:10.1073/pnas.67.3.1608. PMC 283397. PMID 5274483.
  14. ^ Mishra, N. C.; Tatum, E. L. (1973). "Non-Mendelian inheritance of DNA-induced inositol independence in Neurospora". Proceedings of the National Academy of Sciences of the United States of America. 70 (12): 3875–3879. doi:10.1073/pnas.70.12.3875. PMC 427348. PMID 4521213.
  15. ^ Stegmayr, B.; Ronquist, G. (1982). "Promotive effect on human sperm progressive motility by prostasomes". Urological Research. 10 (5): 253–257. doi:10.1007/BF00255932. PMID 6219486. S2CID 26574697.
  16. ^ Raposo, G.; Nijman, H. W.; Stoorvogel, W.; Liejendekker, R.; Harding, C. V.; Melief, C. J.; Geuze, H. J. (1996). "B lymphocytes secrete antigen-presenting vesicles". The Journal of Experimental Medicine. 183 (3): 1161–1172. doi:10.1084/jem.183.3.1161. PMC 2192324. PMID 8642258.
  17. ^ [citation needed]
  18. ^ Mack, Matthias; Kleinschmidt, Andrea; Brühl, Hilke; Klier, Christiane; Nelson, Peter J.; Cihak, Josef; Plachý, Jiurí; Stangassinger, Manfred; Erfle, Volker; Schlöndorff, Detlef (2000). "Transfer of the chemokine receptor CCR5 between cells by membrane-derived microparticles: A mechanism for cellular human immunodeficiency virus 1 infection". Nature Medicine. 6 (7): 769–775. doi:10.1038/77498. PMID 10888925. S2CID 23027144.
  19. ^ Rozmyslowicz, T.; Majka, M.; Kijowski, J.; Murphy, S. L.; Conover, D. O.; Poncz, M.; Ratajczak, J.; Gaulton, G. N.; Ratajczak, M. Z. (2003). "Platelet- and megakaryocyte-derived microparticles transfer CXCR4 receptor to CXCR4-null cells and make them susceptible to infection by X4-HIV". Aids (London, England). 17 (1): 33–42. doi:10.1097/00002030-200301030-00006. PMID 12478067. S2CID 6619801.
  20. ^ Baj-Krzyworzeka, M.; Szatanek, R.; Weglarczyk, K.; Baran, J.; Urbanowicz, B.; Brański, P.; Ratajczak, M. Z.; Zembala, M. (2006). "Tumour-derived microvesicles carry several surface determinants and mRNA of tumour cells and transfer some of these determinants to monocytes". Cancer Immunology, Immunotherapy : Cii. 55 (7): 808–818. doi:10.1007/s00262-005-0075-9. PMID 16283305. S2CID 25723677.
  21. ^ Ratajczak, J.; Wysoczynski, M.; Hayek, F.; Janowska-Wieczorek, A.; Ratajczak, M. Z. (2006). "Membrane-derived microvesicles: Important and underappreciated mediators of cell-to-cell communication". Leukemia. 20 (9): 1487–1495. doi:10.1038/sj.leu.2404296. PMID 16791265. S2CID 6874345.
  22. ^ Aliotta, J. M.; Sanchez-Guijo, F. M.; Dooner, G. J.; Johnson, K. W.; Dooner, M. S.; Greer, K. A.; Greer, D.; Pimentel, J.; Kolankiewicz, L. M.; Puente, N.; Faradyan, S.; Ferland, P.; Bearer, E. L.; Passero, M. A.; Adedi, M.; Colvin, G. A.; Quesenberry, P. J. (2007). "Alteration of marrow cell gene expression, protein production, and engraftment into lung by lung-derived microvesicles: A novel mechanism for phenotype modulation". Stem Cells (Dayton, Ohio). 25 (9): 2245–2256. doi:10.1634/stemcells.2007-0128. PMC 3376082. PMID 17556595.
  23. ^ Valadi, H.; Ekström, K.; Bossios, A.; Sjöstrand, M.; Lee, J. J.; Lötvall, J. O. (2007). "Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells". Nature Cell Biology. 9 (6): 654–659. doi:10.1038/ncb1596. PMID 17486113. S2CID 8599814.
  24. ^ Skog, J.; Würdinger, T.; Van Rijn, S.; Meijer, D. H.; Gainche, L.; Sena-Esteves, M.; Curry Jr, W. T.; Carter, B. S.; Krichevsky, A. M.; Breakefield, X. O. (2008). "Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers". Nature Cell Biology. 10 (12): 1470–1476. doi:10.1038/ncb1800. PMC 3423894. PMID 19011622.
  25. ^ Pegtel, D. M.; Cosmopoulos, K.; Thorley-Lawson, D. A.; Van Eijndhoven, M. A.; Hopmans, E. S.; Lindenberg, J. L.; De Gruijl, T. D.; Würdinger, T.; Middeldorp, J. M. (2010). "Functional delivery of viral miRNAs via exosomes". Proceedings of the National Academy of Sciences of the United States of America. 107 (14): 6328–6333. doi:10.1073/pnas.0914843107. PMC 2851954. PMID 20304794.
  26. ^ Al-Nedawi, K.; Meehan, B.; Rak, J. (2009). "Microvesicles: Messengers and mediators of tumor progression". Cell Cycle (Georgetown, Tex.). 8 (13): 2014–2018. doi:10.4161/cc.8.13.8988. PMID 19535896. S2CID 36391973.
  27. ^ Hoshino, Ayuko; et al. (2015). "Tumour exosome integrins determine organotropic metastasis". Nature. 527 (7578): 329–335. doi:10.1038/nature15756. PMC 4788391. PMID 26524530.
  28. ^ Peinado, H.; Alečković, M.; Lavotshkin, S.; Matei, I.; Costa-Silva, B.; Moreno-Bueno, G.; Hergueta-Redondo, M.; Williams, C.; García-Santos, G.; Ghajar, C.; Nitadori-Hoshino, A.; Hoffman, C.; Badal, K.; Garcia, B. A.; Callahan, M. K.; Yuan, J.; Martins, V. R.; Skog, J.; Kaplan, R. N.; Brady, M. S.; Wolchok, J. D.; Chapman, P. B.; Kang, Y.; Bromberg, J.; Lyden, D. (2012). "Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET". Nature Medicine. 18 (6): 883–891. doi:10.1038/nm.2753. PMC 3645291. PMID 22635005.
  29. ^ Melo, S. A.; Sugimoto, H.; O'Connell, J. T.; Kato, N.; Villanueva, A.; Vidal, A.; Qiu, L.; Vitkin, E.; Perelman, L. T.; Melo, C. A.; Lucci, A.; Ivan, C.; Calin, G. A.; Kalluri, R. (2014). "Cancer exosomes perform cell-independent microRNA biogenesis and promote tumorigenesis". Cancer Cell. 26 (5): 707–721. doi:10.1016/j.ccell.2014.09.005. PMC 4254633. PMID 25446899.
  30. ^ Kamerkar, S.; Lebleu, V. S.; Sugimoto, H.; Yang, S.; Ruivo, C. F.; Melo, S. A.; Lee, J. J.; Kalluri, R. (2017). "Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer". Nature. 546 (7659): 498–503. doi:10.1038/nature22341. PMC 5538883. PMID 28607485.
  31. ^ Ostrowski, M.; Carmo, N. B.; Krumeich, S.; Fanget, I.; Raposo, G.; Savina, A.; Moita, C. F.; Schauer, K.; Hume, A. N.; Freitas, R. P.; Goud, B.; Benaroch, P.; Hacohen, N.; Fukuda, M.; Desnos, C.; Seabra, M. C.; Darchen, F.; Amigorena, S.; Moita, L. F.; Thery, C. (2010). "Rab27a and Rab27b control different steps of the exosome secretion pathway". Nature Cell Biology. 12 (1): 19–30, sup pp 1-13. doi:10.1038/ncb2000. hdl:10044/1/19574. PMID 19966785. S2CID 13935708.
  32. ^ Van Niel, G.; Porto-Carreiro, I.; Simoes, S.; Raposo, G. (2006). "Exosomes: A common pathway for a specialized function". Journal of Biochemistry. 140 (1): 13–21. doi:10.1093/jb/mvj128. PMID 16877764.
  33. ^ Kowal, J.; Arras, G.; Colombo, M.; Jouve, M.; Morath, J. P.; Primdal-Bengtson, B.; Dingli, F.; Loew, D.; Tkach, M.; Théry, C. (2016). "Proteomic comparison defines novel markers to characterize heterogeneous populations of extracellular vesicle subtypes". Proceedings of the National Academy of Sciences of the United States of America. 113 (8): E968-77. doi:10.1073/pnas.1521230113. PMC 4776515. PMID 26858453.
  34. ^ Tkach, M.; Kowal, J.; Théry, C. (2018). "Why the need and how to approach the functional diversity of extracellular vesicles". Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences. 373 (1737). doi:10.1098/rstb.2016.0479. PMC 5717434. PMID 29158309.
  35. ^ Leslie, M. (2013). "Cell Biology. NIH effort gambles on mysterious extracellular RNAs". Science. 341 (6149): 947. doi:10.1126/science.341.6149.947. PMID 23990535.
  36. ^ [citation needed]
  37. ^ [citation needed]
  38. ^ Théry, C.; et al. (2018). "Minimal information for studies of extracellular vesicles 2018 (MISEV2018): A position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines". Journal of Extracellular Vesicles. 7 (1). doi:10.1080/20013078.2018.1535750. PMC 6322352. PMID 30637094.
  39. ^ Théry, C.; et al. (2018). "Minimal information for studies of extracellular vesicles 2018 (MISEV2018): A position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines". Journal of Extracellular Vesicles. 7 (1). doi:10.1080/20013078.2018.1535750. PMC 6322352. PMID 30637094.
  40. ^ Théry, C.; et al. (2018). "Minimal information for studies of extracellular vesicles 2018 (MISEV2018): A position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines". Journal of Extracellular Vesicles. 7 (1). doi:10.1080/20013078.2018.1535750. PMC 6322352. PMID 30637094.
  41. ^ Meehan, B.; Rak, J.; Di Vizio, D. (2016). "Oncosomes - large and small: What are they, where they came from?". Journal of Extracellular Vesicles. 5: 33109. doi:10.3402/jev.v5.33109. PMC 5040817. PMID 27680302.
  42. ^ Parameter error in {{PMID}}: Missing PMID.
  43. ^ Melentijevic, I.; Toth, M. L.; Arnold, M. L.; Guasp, R. J.; Harinath, G.; Nguyen, K. C.; Taub, D.; Parker, J. A.; Neri, C.; Gabel, C. V.; Hall, D. H.; Driscoll, M. (2017). "C. Elegans neurons jettison protein aggregates and mitochondria under neurotoxic stress". Nature. 542 (7641): 367–371. doi:10.1038/nature21362. PMC 5336134. PMID 28178240.
  44. ^ Melentijevic, I.; Toth, M. L.; Arnold, M. L.; Guasp, R. J.; Harinath, G.; Nguyen, K. C.; Taub, D.; Parker, J. A.; Neri, C.; Gabel, C. V.; Hall, D. H.; Driscoll, M. (2017). "C. Elegans neurons jettison protein aggregates and mitochondria under neurotoxic stress". Nature. 542 (7641): 367–371. doi:10.1038/nature21362. PMC 5336134. PMID 28178240.
  45. ^ Théry, C.; et al. (2018). "Minimal information for studies of extracellular vesicles 2018 (MISEV2018): A position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines". Journal of Extracellular Vesicles. 7 (1). doi:10.1080/20013078.2018.1535750. PMC 6322352. PMID 30637094.
  46. ^ Nolte-'t Hoen, E.; Cremer, T.; Gallo, R. C.; Margolis, L. B. (2016). "Extracellular vesicles and viruses: Are they close relatives?". Proceedings of the National Academy of Sciences of the United States of America. 113 (33): 9155–9161. doi:10.1073/pnas.1605146113. PMC 4995926. PMID 27432966.
  47. ^ Zhang, H.; et al. (2018). "Identification of distinct nanoparticles and subsets of extracellular vesicles by asymmetric flow field-flow fractionation". Nature Cell Biology. 20 (3): 332–343. doi:10.1038/s41556-018-0040-4. PMC 5931706. PMID 29459780.
  48. ^ Théry, C.; et al. (2018). "Minimal information for studies of extracellular vesicles 2018 (MISEV2018): A position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines". Journal of Extracellular Vesicles. 7 (1). doi:10.1080/20013078.2018.1535750. PMC 6322352. PMID 30637094.
  49. ^ Mateescu, B.; et al. (2017). "Obstacles and opportunities in the functional analysis of extracellular vesicle RNA - an ISEV position paper". Journal of Extracellular Vesicles. 6 (1). doi:10.1080/20013078.2017.1286095. PMC 5345583. PMID 28326170.
  50. ^ Yáñez-Mó, M.; et al. (2015). "Biological properties of extracellular vesicles and their physiological functions". Journal of Extracellular Vesicles. 4: 27066. doi:10.3402/jev.v4.27066. PMC 4433489. PMID 25979354.
  51. ^ Lacroix, R.; Judicone, C.; Poncelet, P.; Robert, S.; Arnaud, L.; Sampol, J.; Dignat-George, F. (2012). "Impact of pre-analytical parameters on the measurement of circulating microparticles: Towards standardization of protocol". Journal of Thrombosis and Haemostasis : JTH. 10 (3): 437–446. doi:10.1111/j.1538-7836.2011.04610.x. PMID 22212198. S2CID 46519893.
  52. ^ Witwer, K. W.; Buzás, E. I.; Bemis, L. T.; Bora, A.; Lässer, C.; Lötvall, J.; Nolte-'t Hoen, E. N.; Piper, M. G.; Sivaraman, S.; Skog, J.; Théry, C.; Wauben, M. H.; Hochberg, F. (2013). "Standardization of sample collection, isolation and analysis methods in extracellular vesicle research". Journal of Extracellular Vesicles. 2: 20360. doi:10.3402/jev.v2i0.20360. PMC 3760646. PMID 24009894.
  53. ^ Coumans, Frank A.W.; Brisson, Alain R.; Buzas, Edit I.; Dignat-George, Françoise; Drees, Esther E.E.; El-Andaloussi, Samir; Emanueli, Costanza; Gasecka, Aleksandra; Hendrix, An; Hill, Andrew F.; Lacroix, Romaric; Lee, Yi; Van Leeuwen, Ton G.; MacKman, Nigel; Mäger, Imre; Nolan, John P.; Van Der Pol, Edwin; Pegtel, D. Michiel; Sahoo, Susmita; Siljander, Pia R.M.; Sturk, Guus; De Wever, Olivier; Nieuwland, Rienk (2017). "Methodological Guidelines to Study Extracellular Vesicles". Circulation Research. 120 (10): 1632–1648. doi:10.1161/CIRCRESAHA.117.309417. PMID 28495994. S2CID 13857781.
  54. ^ Lötvall, J.; Hill, A. F.; Hochberg, F.; Buzás, E. I.; Di Vizio, D.; Gardiner, C.; Gho, Y. S.; Kurochkin, I. V.; Mathivanan, S.; Quesenberry, P.; Sahoo, S.; Tahara, H.; Wauben, M. H.; Witwer, K. W.; Théry, C. (2014). "Minimal experimental requirements for definition of extracellular vesicles and their functions: A position statement from the International Society for Extracellular Vesicles". Journal of Extracellular Vesicles. 3: 26913. doi:10.3402/jev.v3.26913. PMC 4275645. PMID 25536934.
  55. ^ Théry, C.; et al. (2018). "Minimal information for studies of extracellular vesicles 2018 (MISEV2018): A position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines". Journal of Extracellular Vesicles. 7 (1). doi:10.1080/20013078.2018.1535750. PMC 6322352. PMID 30637094.
Retrieved from "https://wiki.riteme.site/w/index.php?title=User:H2OBear/sandbox&oldid=1137813439"